Could this startup really disrupt the pharmaceutical industry?

The COVID-19 pandemic stomped on the exercise as people baked banana bread and sat on the couch. As the pandemic wanes, people have become more health conscious as they try to end this sedentary lifestyle. In addition to healthier eating habits and regular physical activity, people are consuming a wider variety of dietary supplements daily.

The global dietary supplements market is expected to grow at a compound annual growth rate (CAGR) of 8.5% over the next eight years, according to a report published by Facts and Factors.

TruBrain manufactures high performance brain foods and nootropics designed to improve mental performance, increase verbal fluency and overcome procrastination. He recently received FDA clearance to move forward with TruBrain’s new wearable device applications, designed to soothe the central nervous system through vibrotherapy.

Disrupting the pharmaceutical industry

Although not a pharmaceutical company, TruBrain employs UCLA-trained neuroscientists to create sophisticated brain foods. Most nootropics in TruBrain show benefits within 45 minutes of consumption on average and typically last all day. However, some customers have reported feeling the effect within 7-10 days as their body adapts to the nutrients.

Since its inception in 2012, TruBrain has generated over $18 million in lifetime sales. It has shipped over 6 million drinks worldwide and has an average order value of $64. Moreover, the company has been profitable since 2019. The start-up is set to become a household name in the cognitive health industry in the coming years.

Trial program for skeptics

TruBrain offers a 14-day trial box for US-based customers that contains ten one-ounce doses. Following this, people who choose to remain registered receive a box of 20 of the most popular drinks each month, with the option to cancel at any time. It also allows customers to build a personalized drink box, based on their cognitive needs.

Plus, it crafts the shots with seven unique, patent-pending formulas featuring nootropics, minerals, hemp, and functional oils.

Support from leading investors

TruBrain has raised over $3.8 million from leading venture capitalists, including 500 Startups and Sherpa Venture Capita. Other than that, the platform has raised $1.7 million in previous Regulatory A+ and crowdfunding rounds. It currently has more than 2,000 social investors.

Crowdfunding investment opportunity

TruBrain’s latest crowdfunding round has so far raised over $1 million from retail investors. The startup currently has an enterprise valuation of $24.3 million. Investors can take a stake in TruBrain for 43 cents per share through its latest crowdfunding round on Start the engine.

With an international customer base in eight countries, TruBrain is poised to carve out a strong foothold in the $38 billion personalized healthcare market.

Don’t miss real-time alerts on your actions – join BenzingaPro free! Try the tool that will help you invest smarter, faster and better.

© 2022 Benzinga does not provide investment advice. All rights reserved.